Actigraphy as an assessment of performance status in patients with advanced lung cancer

Daisuke Fujisawa, Jennifer S. Temel, Joseph A. Greer, Areej El-Jawahri, Lara Traeger, Jamie M. Jacobs, Stacy Cutrono, William F. Pirl

Research output: Contribution to journalArticle

Abstract

ObjectiveWearable devices such as a wrist actigraph may have a potential to objectively estimate patients' functioning and may supplement performance status (PS). This proof-of-concept study aimed to evaluate whether actigraphy data are significantly associated with patients' functioning and are predictive of their survival in patients with metastatic non-small cell lung cancer.MethodWe collected actigraphy data for a three-day period in ambulatory patients with stage IV non-small cell lung cancer. We computed correlations between actigraphy data (specifically, proportion of time spent immobile while awake) and clinician-rated PS, subjective report of physical activities, quality of life (the Functional Assessment of Cancer Therapy-Trial Outcome Index), and survival.ResultActigraphy data (the proportion of time awake spent immobile) were significantly correlated with Functional Assessment of Cancer Therapy-Trial Outcome Index (r = ?irc;'0.53, p < 0.001) and with the Eastern Cooperative Oncology Group PS (ECOG PS) (r = 0.37, p < 0.001). The proportion of time awake spent immobile was significantly associated with worse survival. For each 10% increase in this measure, the hazard ratio (HR) was 1.48 (95% confidence interval [CI 95% ] = 1.06, 2.06) for overall mortality, and odds ratio was 2.99 (CI 95% = 1.27, 7.05) for six-month mortality. ECOG PS was also associated with worse survival (HR = 2.80, CI 95% = 1.34, 5.86). Among patients with ECOG PS 0-1, the percentage of time awake spent immobile was significantly associated with worse survival, HR = 1.93 (CI 95% = 1.10, 3.42), whereas ECOG PS did not predict survival.Significance of ResultsActigraphy may have potential to predict important clinical outcomes, such as quality of life and survival, and may serve to supplement PS. Further validation study is warranted.

Original languageEnglish
JournalPalliative and Supportive Care
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Actigraphy
Lung Neoplasms
Survival
Non-Small Cell Lung Carcinoma
Quality of Life
Mortality
Validation Studies
Wrist
Neoplasms
Odds Ratio
Confidence Intervals
Exercise
Equipment and Supplies
Therapeutics

Keywords

  • Actigraph
  • Cancer
  • Performance status
  • Physical activity
  • Survival

ASJC Scopus subject areas

  • Nursing(all)
  • Clinical Psychology
  • Psychiatry and Mental health

Cite this

Actigraphy as an assessment of performance status in patients with advanced lung cancer. / Fujisawa, Daisuke; Temel, Jennifer S.; Greer, Joseph A.; El-Jawahri, Areej; Traeger, Lara; Jacobs, Jamie M.; Cutrono, Stacy; Pirl, William F.

In: Palliative and Supportive Care, 01.01.2019.

Research output: Contribution to journalArticle

Fujisawa, Daisuke ; Temel, Jennifer S. ; Greer, Joseph A. ; El-Jawahri, Areej ; Traeger, Lara ; Jacobs, Jamie M. ; Cutrono, Stacy ; Pirl, William F. / Actigraphy as an assessment of performance status in patients with advanced lung cancer. In: Palliative and Supportive Care. 2019.
@article{687aaf61fe5444b192771bf00237b805,
title = "Actigraphy as an assessment of performance status in patients with advanced lung cancer",
abstract = "ObjectiveWearable devices such as a wrist actigraph may have a potential to objectively estimate patients' functioning and may supplement performance status (PS). This proof-of-concept study aimed to evaluate whether actigraphy data are significantly associated with patients' functioning and are predictive of their survival in patients with metastatic non-small cell lung cancer.MethodWe collected actigraphy data for a three-day period in ambulatory patients with stage IV non-small cell lung cancer. We computed correlations between actigraphy data (specifically, proportion of time spent immobile while awake) and clinician-rated PS, subjective report of physical activities, quality of life (the Functional Assessment of Cancer Therapy-Trial Outcome Index), and survival.ResultActigraphy data (the proportion of time awake spent immobile) were significantly correlated with Functional Assessment of Cancer Therapy-Trial Outcome Index (r = ?irc;'0.53, p < 0.001) and with the Eastern Cooperative Oncology Group PS (ECOG PS) (r = 0.37, p < 0.001). The proportion of time awake spent immobile was significantly associated with worse survival. For each 10{\%} increase in this measure, the hazard ratio (HR) was 1.48 (95{\%} confidence interval [CI 95{\%} ] = 1.06, 2.06) for overall mortality, and odds ratio was 2.99 (CI 95{\%} = 1.27, 7.05) for six-month mortality. ECOG PS was also associated with worse survival (HR = 2.80, CI 95{\%} = 1.34, 5.86). Among patients with ECOG PS 0-1, the percentage of time awake spent immobile was significantly associated with worse survival, HR = 1.93 (CI 95{\%} = 1.10, 3.42), whereas ECOG PS did not predict survival.Significance of ResultsActigraphy may have potential to predict important clinical outcomes, such as quality of life and survival, and may serve to supplement PS. Further validation study is warranted.",
keywords = "Actigraph, Cancer, Performance status, Physical activity, Survival",
author = "Daisuke Fujisawa and Temel, {Jennifer S.} and Greer, {Joseph A.} and Areej El-Jawahri and Lara Traeger and Jacobs, {Jamie M.} and Stacy Cutrono and Pirl, {William F.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1017/S1478951518001074",
language = "English",
journal = "Palliative and Supportive Care",
issn = "1478-9515",
publisher = "Cambridge University Press",

}

TY - JOUR

T1 - Actigraphy as an assessment of performance status in patients with advanced lung cancer

AU - Fujisawa, Daisuke

AU - Temel, Jennifer S.

AU - Greer, Joseph A.

AU - El-Jawahri, Areej

AU - Traeger, Lara

AU - Jacobs, Jamie M.

AU - Cutrono, Stacy

AU - Pirl, William F.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - ObjectiveWearable devices such as a wrist actigraph may have a potential to objectively estimate patients' functioning and may supplement performance status (PS). This proof-of-concept study aimed to evaluate whether actigraphy data are significantly associated with patients' functioning and are predictive of their survival in patients with metastatic non-small cell lung cancer.MethodWe collected actigraphy data for a three-day period in ambulatory patients with stage IV non-small cell lung cancer. We computed correlations between actigraphy data (specifically, proportion of time spent immobile while awake) and clinician-rated PS, subjective report of physical activities, quality of life (the Functional Assessment of Cancer Therapy-Trial Outcome Index), and survival.ResultActigraphy data (the proportion of time awake spent immobile) were significantly correlated with Functional Assessment of Cancer Therapy-Trial Outcome Index (r = ?irc;'0.53, p < 0.001) and with the Eastern Cooperative Oncology Group PS (ECOG PS) (r = 0.37, p < 0.001). The proportion of time awake spent immobile was significantly associated with worse survival. For each 10% increase in this measure, the hazard ratio (HR) was 1.48 (95% confidence interval [CI 95% ] = 1.06, 2.06) for overall mortality, and odds ratio was 2.99 (CI 95% = 1.27, 7.05) for six-month mortality. ECOG PS was also associated with worse survival (HR = 2.80, CI 95% = 1.34, 5.86). Among patients with ECOG PS 0-1, the percentage of time awake spent immobile was significantly associated with worse survival, HR = 1.93 (CI 95% = 1.10, 3.42), whereas ECOG PS did not predict survival.Significance of ResultsActigraphy may have potential to predict important clinical outcomes, such as quality of life and survival, and may serve to supplement PS. Further validation study is warranted.

AB - ObjectiveWearable devices such as a wrist actigraph may have a potential to objectively estimate patients' functioning and may supplement performance status (PS). This proof-of-concept study aimed to evaluate whether actigraphy data are significantly associated with patients' functioning and are predictive of their survival in patients with metastatic non-small cell lung cancer.MethodWe collected actigraphy data for a three-day period in ambulatory patients with stage IV non-small cell lung cancer. We computed correlations between actigraphy data (specifically, proportion of time spent immobile while awake) and clinician-rated PS, subjective report of physical activities, quality of life (the Functional Assessment of Cancer Therapy-Trial Outcome Index), and survival.ResultActigraphy data (the proportion of time awake spent immobile) were significantly correlated with Functional Assessment of Cancer Therapy-Trial Outcome Index (r = ?irc;'0.53, p < 0.001) and with the Eastern Cooperative Oncology Group PS (ECOG PS) (r = 0.37, p < 0.001). The proportion of time awake spent immobile was significantly associated with worse survival. For each 10% increase in this measure, the hazard ratio (HR) was 1.48 (95% confidence interval [CI 95% ] = 1.06, 2.06) for overall mortality, and odds ratio was 2.99 (CI 95% = 1.27, 7.05) for six-month mortality. ECOG PS was also associated with worse survival (HR = 2.80, CI 95% = 1.34, 5.86). Among patients with ECOG PS 0-1, the percentage of time awake spent immobile was significantly associated with worse survival, HR = 1.93 (CI 95% = 1.10, 3.42), whereas ECOG PS did not predict survival.Significance of ResultsActigraphy may have potential to predict important clinical outcomes, such as quality of life and survival, and may serve to supplement PS. Further validation study is warranted.

KW - Actigraph

KW - Cancer

KW - Performance status

KW - Physical activity

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85061363311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061363311&partnerID=8YFLogxK

U2 - 10.1017/S1478951518001074

DO - 10.1017/S1478951518001074

M3 - Article

JO - Palliative and Supportive Care

JF - Palliative and Supportive Care

SN - 1478-9515

ER -